Sanuwave
MN - Eden PrairieBiotechnology
Focus: Sanuwave is a newly founded biotechnology company specializing in shock wave technology for tissue repair and regeneration, with a focus on diabetic foot ulcers. The company is pre-revenue and operating as a clinical-stage biotech with multiple Phase 3 programs in development.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Open Jobs
0
About Sanuwave
AI assessmentNot HiringNo open roles listed right now. Follow Sanuwave to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
dermaPACE
Diabetic Foot UlcerClinical Trials (1)
NCT03640988The Effects of High Energy Acoustic Shock Wave Therapy on Local Skin Perfusion and DFUs
N/AHelp build intelligence for Sanuwave
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.